Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L E Flaherty

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
The Cancer Journal From Scientific American|February 24, 2000
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanomaL E Flaherty
Current Oncology Reports|December 21, 2000
Biochemotherapy for melanomaP A Philip, L E Flaherty
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Adjuvant high-dose interferon revisitedV K Sondak, L E Flaherty
Journal of the National Cancer Institute|August 15, 1990
Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanomaL E Flaherty, R Schwert, B G Redman
American Journal of Clinical Oncology|December 10, 1997
Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanomaL E Flaherty, P Y Liu, J Unger, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patientsG G Chabot, L E Flaherty, M Valdivieso, et al.
American Journal of Clinical Oncology|October 1, 1996
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostateK J Pienta, B G Redman, P S Esper, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1986
Infection of T4 lymphocytes by HTLV-III does not require expression of the OKT4 epitopeJ A Hoxie, L E Flaherty, B S Haggarty, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinomaB G Redman, Y Abubakr, T Chou, et al.
American Journal of Clinical Oncology|February 1, 1997
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostateK J Pienta, P S Esper, F Zwas, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The Cancer Journal From Scientific American|February 24, 2000
Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanomaL E Flaherty
Current Oncology Reports|December 21, 2000
Biochemotherapy for melanomaP A Philip, L E Flaherty
Cancer Journal (Sudbury, Mass.)|July 6, 2000
Adjuvant high-dose interferon revisitedV K Sondak, L E Flaherty
Journal of the National Cancer Institute|August 15, 1990
Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanomaL E Flaherty, R Schwert, B G Redman
American Journal of Clinical Oncology|December 10, 1997
Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanomaL E Flaherty, P Y Liu, J Unger, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patientsG G Chabot, L E Flaherty, M Valdivieso, et al.
American Journal of Clinical Oncology|October 1, 1996
A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostateK J Pienta, B G Redman, P S Esper, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 1, 1986
Infection of T4 lymphocytes by HTLV-III does not require expression of the OKT4 epitopeJ A Hoxie, L E Flaherty, B S Haggarty, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinomaB G Redman, Y Abubakr, T Chou, et al.
American Journal of Clinical Oncology|February 1, 1997
Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostateK J Pienta, P S Esper, F Zwas, et al.
Pageof 4